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Allogeneic hematopoietic stem cell transplantation 
is a therapy for hematopoietic malignancies in 
which cure is achieved by immune-mediated 
graft-versus-leukemia (GVL) effects. Graft-
versus-host disease (GVHD) is a similar pro-
cess whereby normal tissue, particularly that 
in gastrointestinal (GI) tract, skin, and liver, is 
targeted and represents the major limitation of 
this therapy (Ferrara et al., 2009; Gooley et al., 
2010; Weisdorf et al., 2012). Host alloantigens, 
derived from polymorphic proteins, can be pre-
sented to donor T cells by host APCs (direct 
presentation) or by donor APCs after uptake 
of cellular material from damaged host target 
tissue (indirect presentation; Chakraverty and 
Sykes, 2007; Joffre et al., 2012). In MHC class 
I–dependent GVHD, host hematopoietic APCs 
have been shown to be critical for disease, and 
donor APCs can amplify this effect (Shlomchik 
et al., 1999; Matte et al., 2004). Recently, we have 
shown that MHC class II–dependent GVHD 
may be initiated by nonhematopoietic APCs 
and donor hematopoietic APCs in isolation are 
inefficient in initiating disease (MacDonald 
et al., 2007; Markey et al., 2009; Koyama et al., 
2012; Toubai et al., 2012). However, the rela-
tive importance of donor indirect alloantigen 
presentation to GVHD and the cellular and 
molecular contexts involved have not been es-
tablished in clinically relevant systems where 
GVHD has been initiated by recipient antigen 
presentation. Given that donor APCs are es-
sential to provide pathogen-specific immune 
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The primacy of the gastrointestinal (GI) tract in dictating the outcome of graft-versus-host 
disease (GVHD) is broadly accepted; however, the mechanisms controlling this effect are 
poorly understood. Here, we demonstrate that GVHD markedly enhances alloantigen pre-
sentation within the mesenteric lymph nodes (mLNs), mediated by donor CD103+CD11b 
dendritic cells (DCs) that migrate from the colon under the influence of CCR7. Expansion 
and differentiation of donor T cells specifically within the mLNs is driven by profound levels 
of alloantigen, IL-12, and IL-6 promoted by Toll-like receptor (TLR) and receptor for ad-
vanced glycation end products (RAGE) signals. Critically, alloantigen presentation in the 
mLNs imprints gut-homing integrin signatures on donor T cells, leading to their emigration 
into the GI tract where they mediate fulminant disease. These data identify a critical, 
anatomically distinct, donor DC subset that amplifies GVHD. We thus highlight multiple 
therapeutic targets and the ability of GVHD, once initiated by recipient antigen-presenting 
cells, to generate a profound, localized, and lethal feed-forward cascade of donor DC–
mediated indirect alloantigen presentation and cytokine secretion within the GI tract.
© 2015 Koyama et al. This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months 
it is available under a Creative Commons License (Attribution–Noncommercial–
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Figure 1. Donor alloantigen presentation during GVHD drives T cell accumulation and expansion in the mLNs. BALB/c mice were transplanted with 
TCD BM from B6.WT or B6.H2-Ab1/ mice, with or without B6.WT T cells (“BM + T” or “TCD BM”). On day 12 TEaluc+ cells were injected, and 1, 3, or 5 d later BLI 
signals were quantified. (a) Experimental schema. (b and c) Representative images (b) and quantification (c) of BLI signals in mLNs and gut from the recipients of 
BM + T. Data shown are combined from three replicate experiments (n = 9, 6, and 7 per time point). ****, P < 0.0001; **, P = 0.0032; *, P = 0.035. Li, liver; SI, small 
intestine; Sp, spleen; Thy, thymus. (d–g) Ratio of BLI signals from the recipients of B6.WT BM to those from the recipients of B6.H2-Ab1/ BM 1 (d), 3 (e), and 5 d 
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TEa TCR transgenic CD4+ T cell that expresses luciferase 
and possesses a TCR specific for (BALB/c) host-derived I-Ed 
peptide when presented within the (B6) donor I-Ab molecule 
(Ochando et al., 2006; Markey et al., 2009; Koyama et al., 
2012). To delineate the mechanisms by which donor APCs 
maintain acute GVHD, WT B6 or I-Ab–deficient B6 (B6.
H2Ab1/) donor BM was transplanted, with or without 
B6.WT T cells, into lethally irradiated BALB/c recipients. 
The B6.WT T cells initiate GVHD in response to host APCs 
in this system regardless of the expression of MHC class II 
within donor APCs (Koyama et al., 2012). 12 d later, when 
donor-derived APCs had reconstituted, luciferase-expressing 
TEa (TEaluc+) cells were transferred. In this model, the TEa cells 
can respond only to host alloantigen presented within donor 
MHC class II (I-Ab). TEa expansion is thus a measurement of 
responses, approaches targeting the whole donor APC com-
partment are likely to be deleterious, and a clear understand-
ing of this process in total is needed to optimize appropriate 
therapeutic interventions. Here we delineate the temporal and 
spatial context of donor alloantigen presentation and uncover 
an unappreciated and critical role for acute GVHD in driving 
antigen presentation specifically within the GI tract that leads 
to a feed-forward cascade culminating in lethality.
RESULTS
Donor alloantigen presentation during GVHD drives  
T cell expansion in the mesenteric LNs (mLNs)
We developed a model of GVHD whereby the donor T cell 
response is directed to a single host allogeneic peptide presented 
within donor MHC class II. This system utilizes a B6-derived 
(g) after TEaluc+ cell injection by mixed-model analysis and representative images on day 12 + 5 (f). ****, P < 0.0001; **, P = 0.001 (day 12 + 3, BM + T); **, P = 0.004 
(day 12 + 5, TCD BM) versus whole body (d, e, and g), except BM + T versus TCD BM for mLNs or iLNs, P = 0.51 (d) and ****, P < 0.0001 (g and e). Data shown are 
combined from two replicate experiments, respectively (n = 10 [d], 7–12 [e], and 7–11 [g] per group). (h) BALB/c mice were transplanted with TCD BM from B6.WT 
or B6.H2-Ab1/ mice with or without B6.WT T cells and/or TEaluc+ cells on day 0. GVHD survival is combined from three replicate experiments (n = 18 per group 
in groups of B6.WT BM with TEa and 12 in the other groups). ****, P < 0.0001 as indicated. Data are represented as mean ± SEM.
 
Figure 2. MHC class I–dependent alloantigen and third party antigen presentation in the mLNs. (a and b) Lethally irradiated female or male BALB/c 
recipients (CD45.1+CD45.2) were transplanted with BM and T cells from female B6 (CD45.1+CD45.2) mice. On day 12 female CFSE-labeled HY-TCR CD8 Tg cells 
(CD45.1CD45.2+) were injected, and 4 d later spleen, mLNs, and iLNs were isolated. Representative CFSE dilution plots (a) and absolute numbers of HY-TCR CD8 
Tg cells detected as V8+CD8+CD45.2+ cells (b). Data shown (n = 5–6 per group) are representative of two replicate experiments. **, P = 0.0043; *, P = 0.0209. 
(c and d) Lethally irradiated BALB/c recipients were transplanted with BM from B6.WT or B6.CD11c.ova mice and B6.WT T cells. On day 12 CFSE-labeled OT-II 
cells were injected, and 3 d later spleen, mLNs, and iLNs were isolated. Representative CFSE dilution plots (c) and absolute numbers of OT-II cells detected as 
V5+V2+CD4+ cells (d). Data shown are combined from two replicate experiments (n = 11–12 per group). ***, P = 0.0003. Data are represented as mean ± SEM.
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Figure 3. Alloantigen is preferentially presented by donor DCs in the mLNs during GVHD. (a and b) BALB/c mice were transplanted with TCD BM 
from B6.WT or B6.CD11c.DTR mice and B6.WT T cells, followed by DT administration. TEaluc+ cells injected on day 12 were quantified 3 d later. (a) Representa-
tive images. (b) The ratio of BLI signals from donor DC-replete mice to those from DC-deleted mice by mixed-model analysis are combined from two replicate 
experiments (n = 9 per group). ***, P = 0.00016 versus whole body. (c) Proliferation of TEa cells stimulated with DCs isolated at day 12 from BALB/c recipient 
mice transplanted with BM and T cells from B6.WT mice, as determined by [3H]thymidine uptake. **, P = 0.0020 (DC; 5 × 104) or 0.0065 (DC; 2.5 × 104); mLN 
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a and b). In contrast, only homeostatic proliferation was seen 
in female recipients. To compare these findings with alloan-
tigen to a third party antigen, BALB/c mice were trans-
planted with BM from B6.WT or B6.CD11c-OVA transgenic 
mice (where OVA is driven by the CD11c promoter and is 
not derived from host) and B6.WT T cells. In this setting, the 
highest levels of OVA-specific OT-II proliferation and ex-
pansion were observed in spleen (Fig. 2, c and d), with only 
low-level homeostatic proliferation in the recipients of WT 
BM. These data confirm alloantigen to be preferentially pre-
sented by donor APCs within the mLNs, particularly within 
MHC class II.
Alloantigen is preferentially presented  
by donor DCs in the mLNs during GVHD
We next analyzed the role of donor DCs in the organ-specific 
indirect alloantigen presentation because they have been sug-
gested as the primary APCs responsible for indirect alloantigen 
presentation (Markey et al., 2009). Lethally irradiated BALB/c 
mice were transplanted with BM from B6.WT or B6.CD11c-
DTR mice (where diphtheria toxin [DT] receptor [DTR] is 
driven by CD11c promoter) and B6.WT T cells, and DT was 
administered to deplete donor DCs. The absence of donor 
DCs elicited a striking reduction in T cell expansion, again 
primarily within the mLNs (Fig. 3, a and b), suggesting that 
donor DCs were indeed the crucial APCs presenting alloanti-
gen at this site. To further confirm this specialized ability of 
donor DCs within the mLNs to induce alloreactive T cell 
responses, donor DCs from mLNs, peripheral LNs (pLNs), and 
spleen of transplanted BALB/c recipients were purified after 
BMT and co-cultured with TEa cells ex vivo. This confirmed 
that the highest level of alloantigen presentation in donor DCs 
was from mLNs (Fig. 3 c). This did not appear related to dif-
ferences in activation because costimulatory molecule expres-
sion (CD40, CD80, or CD86) was not specifically increased 
in DCs in the mLNs (Fig. 3 d). Because acute GVHD in the 
GI tract is a Th1 (and to a lesser extent Th17)-driven disease 
(Markey et al., 2014), we investigated whether cytokines such 
as IL-12, secreted by DCs, may be providing costimulatory 
signals in the mLNs. Imaging and conventional flow cytomet-
ric analysis indeed confirmed high levels of IL-12p40 and allo-
antigen presentation (YAe+) by donor DCs specifically within 
the mLNs (Fig. 3, e and f).
The mLN CD103+CD11b DC subset  
presents alloantigen and secretes IL-12
We next determined which DC subsets were critical for indi-
rect alloantigen presentation. Subset analysis of donor DCs in 
indirect alloantigen presentation by donor APCs in isolation 
and is quantified by bioluminescence imaging (BLI; Fig. 1 a). 
We first analyzed the temporal and spatial presentation of 
alloantigen by donor APCs in recipients with or without acute 
GVHD. Although TEa cells were seen in the GI tract 1 d after 
injection, they exclusively accumulated within the mLNs 
within 3 d of injection and subsequently expanded therein. 
Within 5 d of injection, they had redistributed into the GI 
tract (Fig. 1, b and c).
To compare the relative importance of indirect alloantigen 
presentation within individual organs, we calculated the aver-
age ratio of each organ to its “control,” that is, the recipients 
of B6.H2Ab1/ BM grafts where alloantigen presentation by 
donor APCs was absent and the BLI signal from TEa cells re-
flected homeostatic proliferation. We then used mixed-model 
analysis (Cochran and Cox, 1957) to allow us to compare or-
gans from the same mouse. This demonstrated that 1 d after 
injection TEa cells distribute almost equally between organs, 
with only the mLNs demonstrating an alloantigen-specific 
signal, an effect independent of GVHD at this time point 
(Fig. 1 d). 3 d after injection, this alloantigen-specific signal in 
the mLNs had further amplified in animals with GVHD, with 
moderate signals now detectable in mLNs and inguinal LNs 
(iLNs) in animals without GVHD (Fig. 1 e). By day 5, an 
alloantigen-specific signal was also seen in the GI tract (Fig. 1, 
f and g) in the animals with GVHD, and thus GVHD itself 
resulted in enhanced indirect alloantigen presentation in the 
mLNs and GI tract (Fig. 1, e and g). To confirm that GVHD 
could itself induce indirect alloantigen presentation and ag-
gravate GVHD once initiated by host APCs, TEa cells were 
transplanted into BALB/c recipients with or without B6.WT 
T cells on day 0. Surprisingly, the initiation of GVHD by host 
APCs induced lethal disease thereafter that was driven primar-
ily by donor antigen presentation (Fig. 1 h). These data sug-
gest that, in the presence of GVHD, the mLN is a preferential 
site of indirect alloantigen presentation early after BM trans-
plant (BMT), and this precedes the infiltration of alloreactive 
donor T cells into the GI tract.
We next examined whether this phenomenon held true 
for CD8+ T cells responding to recipient alloantigen pre-
sented within donor MHC class I. Male or female BALB/c.
CD45.1+ recipients were transplanted with BM and T cells 
from B6.CD45.1+ mice and 12 d later injected with CFSE-
labeled B6.CD45.2+ H-2Db–restricted HY-reactive transgenic 
CD8+ reporter T cells (HY-TCR CD8 Tg) that react exclu-
sively to recipient male antigen presented with donor MHC 
class I (H-2Db). HY-TCR CD8 Tg cells accumulated again in 
the mLNs of male BMT recipients 4 d after transfer (Fig. 2, 
versus pLN. ****, P < 0.0001 (DC; 5 × 104, 2.5 × 104); mLN versus spleen (Sp). (d) Representative FACS plots at day 12 after BMT of BALB/c (CD45.2+) recipients 
receiving BM and T cells from B6.CD45.1+ mice. (c and d) Data are representative of two replicate experiments. (e and f) BALB/c mice (I-Ad+) were transplanted 
with BM and T cells from B6.IL-12p40YFP mice. Donor DCs (IA/IE+CD11c+I-Ad7AAD) from spleen, mLNs, and pLNs were FACS sorted (e) or unsorted (f) on 
day 12. (e) Representative pictures (left) and quantification (right) of imaging flow cytometry for IL-12p40YFP and YAe are shown from three replicate experi-
ments. (f) The frequency of YFP+YAe+ cells in the IA/IE+CD11c+I-Ad7AAD population was quantified by conventional flow cytometry. Data shown are com-
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Figure 4. The mLN CD103+CD11b DC subset presents alloantigen and secretes IL-12. (a and b) BALB/c mice were transplanted with BM and  
T cells from B6.IL-12p40-YFP mice. mLNs were isolated on day 12. Representative FACS plots (a) and quantification (b) of YFP, YAe, or CCR7 expression on 
DC subsets discriminated by CD103 and CD11b expression. Data shown are combined from two replicate experiments (n = 13). ****, P < 0.0001; **, P = 
0.0031. (c–h) BALB/c mice were transplanted with TCD BM from B6.WT or B6.IRF4/ mice and B6.WT T cells. On day 12 TEaluc+ cells were injected, and 3 d 
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BM and enhanced within the gut (Fig. 5, d–f). We confirmed 
this result using B6.WT BM or B6.CSF-1R/ BM, which 
was isolated from fetal liver chimeras (FLCs) because CSF-1R 
deficiency is neonatally lethal in B6 mice. CD64+CD11bhi 
macrophages were again specifically reduced in the recipients 
of B6.CSF-1R/ BM and alloantigen-specific T cell expan-
sion was again intact in the mLNs and increased in the gut, 
relative to recipients of B6.WT FLC BM (Fig. 5, g–i). Thus, 
donor CD64+CD11bhi macrophages are not required for indi-
rect alloantigen presentation and, consistent with previous 
studies (MacDonald et al., 2010; Hashimoto et al., 2011), are 
likely to play a suppressive role in acute GVHD.
Damage-associated molecular pattern (DAMP)/pathogen-
associated molecular pattern (PAMP) signals drive 
alloantigen presentation by donor CD103+CD11b DCs
We next investigated the factors responsible for the high lev-
els of indirect alloantigen presentation by donor DCs within 
the mLNs. The mLN drains the GI tract, which contains large 
numbers of PAMPs and DAMPs from tissues damaged by 
GVHD, which are sensed by pattern recognition receptors 
(PRRs). These pathways can stimulate antigen presentation 
(Saleh and Trinchieri, 2011; Kondo et al., 2012). TLR signal-
ing through myeloid differentiation protein-88 (MyD88) 
or Toll–IL-1 receptor domain–containing adaptor inducing 
IFN- (TRIF) and receptor for advanced glycation end 
products (RAGE) are well-characterized PRRs (Yamamoto 
et al., 2003; Chen et al., 2008). We analyzed the contribution 
of DAMP/PAMP signaling to indirect alloantigen presenta-
tion by transplanting BALB/c recipients with BM from B6.
MyD88/TRIF/ or B6.RAGE/ donors. In the absence 
of these pathways, TEa expansion driven by indirect alloanti-
gen presentation was decreased specifically within the mLN 
(Fig. 6, a–d). We also noted a significant reduction in the 
CD103+CD11b DC subset in the recipients of MyD88/
TRIF/ or RAGE/ BM and an associated reduction in 
YAe+ and IL-12p40–secreting DCs in the mLN (Fig. 6, e–g). 
The number of CD64+CD11bhi macrophages was not influ-
enced by the absence of MyD88/TRIF or RAGE signaling. 
These data confirm that donor CD103+CD11b DCs in the 
mLNs present alloantigen and secrete IL-12p40 in response 
to DAMP/PAMP signals.
Donor-derived IL-12 and IL-6 drive T cell expansion  
and differentiation in the mLNs in an alloantigen 
presentation–independent manner
Although DAMPs/PAMPs increase cytokine production 
and alloantigen presentation of donor DCs, particularly 
the mLNs discriminated three subsets as CD103+CD11b, 
CD103+CD11b+, and CD103CD11b+ and demonstrated 
that the CD103+CD11b DCs included the highest frequency 
of alloantigen-presenting and IL12p40-producing cells that 
concurrently express high levels of CCR7 (Fig. 4, a and b). 
This led us to hypothesize that donor CD103+CD11b DCs 
may migrate from the GI tract of animals with GVHD to the 
mLNs and prime alloreactive T cells.
To examine whether antigen presentation in the mLNs 
was dependent on the CD103+CD11b DC subset, we used 
B6.IRF4/ mice as BMT donors because they lack the 
CD103+CD11b+ DC subset in the mLNs and the lamina 
propria (Persson et al., 2013; Schlitzer et al., 2013). Donor DCs 
reconstituted from B6.IRF4/ BM were predominantly of 
the CD103+CD11b DC subset (Fig. 4 c). Marked reduc-
tions in both CD11b+ subsets were seen, resulting in an over-
all reduction in DC numbers (Fig. 4 d). However, the total 
numbers of CD103+CD11b DCs and alloantigen-presenting 
(YAe+) DCs were comparable with those in recipients of B6.
WT BM (Fig. 4 d). Of note, CD64+CD11bhi macrophages 
were also comparable between groups. This strategy thus al-
lowed us to study the function of the donor CD103+CD11b 
DC subset after BMT, largely in isolation. As predicted, indi-
rect alloantigen presentation in the mLNs and all other ana-
lyzed organs was equivalent in recipients of B6.IRF4/ and 
B6.WT BM (Fig. 4, e–g), despite the lack of CD11b+ DCs. 
Furthermore, the CD103+CD11b DC subset was sufficient 
to drive T cell differentiation within the mLNs (Fig. 4 h).
CD64+CD11bhi macrophages are dispensable  
for alloantigen presentation
Given that CD64+CD11bhiCD11c+MHC class II+ macrophages 
have been reported as important APCs in T cell–dependent 
colitis models (Tamoutounour et al., 2012), we determined 
whether this subset was also involved in indirect alloantigen 
presentation after BMT. Analysis of donor CD11c+MHC 
class II+ cells in the mLNs demonstrated that CD64+CD11bhi 
macrophages express high levels of the C-C chemokine re-
ceptor 2 (CCR2) and CD115 (the CSF-1 receptor [CSF-
1R]). In contrast, and as expected, expression of CCR2 and 
CD115 by the CD64 DC subsets was negligible (Fig. 5 a; 
Tamoutounour et al., 2012; Alexander et al., 2014). Consis-
tent with this, CD64+CD11bhi macrophage reconstitution in 
the mLNs of BMT recipients of B6.CCR2/ BM was pro-
foundly impaired, whereas reconstitution of all DC subsets 
was intact (Fig. 5, b and c). In spite of this inhibition in macro-
phage reconstitution, indirect alloantigen-specific T cell expan-
sion in the mLNs was comparable in recipients of CCR2/ 
later DC subsets and TEa expansion were analyzed. (c and d) Representative FACS plots (c) and absolute numbers of CD64 DCs, CD103+CD11b DCs, 
YAe+CD64 DCs, and CD64+CD11bhiCD11c+MHC class II+ cells in mLNs (d) are shown. **, P = 0.0011; P = 0.1979 (CD103+CD11b DC), P = 0.1900 (YAe+ DC),  
P = 0.28 (CD64+CD11bhi). (e and f) Representative images (e) and quantification (f) of BLI signals. P = 0.8310. (g) Ratio of BLI signals from B6.WT BM  
recipients to those from B6.IRF4/ BM recipients by mixed-model analysis. (h) Frequency of IFN-, IL-17A, and Foxp3 expression gated on TEa cells de-
tected as V6+V2+CD45.1+ cells. P = 0.1283 (IFN-), P = 0.8343 (IL-17A), P = 0.4597 (Foxp3). (c–h) Data shown are combined from two replicate experi-










Published July 13, 2015
1310 GVHD promotes alloantigen presentation in the gut | Koyama et al.
Figure 5. mLN CD64+CD11bhi macrophages are not required for indirect alloantigen presentation. (a–f) BALB/c mice were transplanted with TCD 
BM from B6.WT or B6.CCR2/ mice and B6.WT T cells. On day 12 TEaluc+ cells were injected, and 3 d later DC subsets and TEa expansion were analyzed. 
(a) Representative FACS plots for the gating strategy (top), CCR2 expression (middle), and CD115 expression (bottom) on CD64+CD11bhi, CD103+CD11b, 
CD103+CD11b+, and CD103CD11b+ subsets in the mLNs from recipients of B6.WT BM. Gray histograms show isotype control. (b and c) Representative FACS 
plots (b) and absolute numbers (c) of the aforementioned subsets from the mLNs. ***, P = 0.0006 (CD64+CD11bhi); n = 7 per group. (d and e) Representative 
images (d) and quantification (e) of BLI signals. P = 0.25 (mLN); *, P = 0.0138 (gut). (f) Ratio of BLI signals from B6.WT BM recipients to those from B6.
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Donor DCs presenting alloantigen  
expand in the colon during GVHD
To evaluate donor DC reconstitution in the presence or ab-
sence of GVHD in a quantitative fashion, BALB/c mice were 
transplanted with BM from B6.CD11c.GCDL mice (lucifer-
ase expression is driven off the CD11c promoter) with or 
without B6.WT T cells. BLI was then used to quantify donor 
CD11c+ DC reconstitution thereafter (Fig. 9 a). The presence 
of GVHD increased donor DC expansion in the second week 
after BMT within both the mLNs and the GI tract (Fig. 9, 
b and c). However, this expansion of donor DCs in animals 
with GVHD was not organ specific at day 12 after BMT 
(Fig. 9 d) and so did not account for the tropism of indirect 
alloantigen presentation for the mLNs. Interestingly, the in-
crease in donor DC expansion in recipients with GVHD was 
seen in the colon but not the small intestine beyond day 12 
(Fig. 9 c). We thus speculated that donor DCs within the 
colon may differ functionally in their capacity to present 
alloantigen to those in the small intestine. Indeed, only co-
lonic DCs were presenting alloantigen (YAe+) and expressing 
IL-12p40 (Fig. 9 e). Furthermore, these DCs only occurred 
in the colon in the presence of GVHD. Indirect alloantigen 
presentation was seen within the CD103+CD11b subset 
(30% of this fraction), the CD103CD11b+ subset, and 
CD64+CD11c+ macrophages (15% of each fraction). IL-
12p40 production was largely restricted to the CD103+CD11b 
subset (Fig. 9 e). These data support the notion that the 
CD103+CD11b DC subset in the colon may play the major 
role in alloreactive T cell activation and expansion, either lo-
cally or within the mLNs after migration. In contrast, indirect 
alloantigen presentation by donor DCs in the small intestine 
is minimal.
Colon-derived donor DCs migrate to the mLNs via CCR7  
and imprint the 47 gut-homing integrin on donor T cells
Because donor T cells rapidly gain access to the GI tract after 
BMT, we next sought to establish whether the initial site of 
antigen presentation by donor APCs to donor T cells was in 
the mLNs or the colon itself. Donor DCs within the mLNs 
express high levels of CCR7 (Fig. 4 a), and we thus used 
CCR7/ donors in BMT experiments to understand the mi-
gratory properties and origin of DCs at this site. Interestingly, 
the absence of CCR7 specifically ablated nearly all donor DC 
subsets (MHC class II+CD11c+CD64) within the mLNs 
after BMT with a resultant accumulation of YAe+ DCs in the 
colon (Fig. 10, a and b). The number of CD64+CD11bhi 
macrophages was not influenced by the absence of CCR7. 
The absence of CCR7 ablated indirect alloantigen presenta-
tion and T cell priming specifically in the mLNs (Fig. 10, c–e) 
CD103+CD11b DCs, we sought to clarify whether concur-
rent cytokine release also influences donor T cell expansion 
and differentiation within the mLNs. The transplantation of 
B6.IL-12p40/ BM confirmed that IL-12 indeed drove 
donor T cell expansion specifically in the mLNs (Fig. 7 a) and 
IL-12 promoted IFN- but not IL-17 nor Foxp3-expressing 
TEa cells (Fig. 7, b and c). Intriguingly, the effect on IFN- 
was independent of any quantitative change to alloantigen 
presentation by DCs in the mLNs (Fig. 7, d and e). Thus, 
IL-12 secretion by donor CD103+CD11b DCs in the mLNs 
directly promotes T cell expansion and differentiation. Next 
we tested the effect of IL-6 secretion from donor BM cells on 
donor alloantigen presentation because blocking of IL-6 re-
ceptor has shown promise in reducing the incidence and se-
verity of acute GVHD, including that within the GI tract, in 
both preclinical studies (Chen et al., 2009; Tawara et al., 2011) 
and clinical trials (Kennedy et al., 2014). Among donor DCs, 
the CD103+CD11b+ subset expressed the highest levels of 
IL-6 mRNA (Fig. 7 f), consistent with studies in other disease 
settings (Persson et al., 2013; Schlitzer et al., 2013). However, 
IL-6 is also known to be produced by most other hematopoi-
etic cells, especially after BMT, including prevalent myeloid 
(e.g., monocytes and neutrophils) and lymphoid lineages 
(Hirano, 1998; Varelias et al., 2015). Of note, Th17 cell dif-
ferentiation was only observed in the mLNs, and we thus 
examined the effects of IL-6 on T cell responses at this site. 
Like IL-12, donor-derived IL-6 also increased TEa expansion 
in the mLNs, and this was an organ-specific effect (Fig. 7 g). 
IL-6 was required for Th17 cell differentiation, but this 
effect was again independent of any quantitative changes to 
alloantigen presentation by DCs in the mLNs (Fig. 7, h–k). 
Although the absence of indirect alloantigen presentation 
itself abrogated TEa expansion and differentiation in total 
(Figs. 1 and 8 a), the relative requirements of MHC class II 
for Th1 versus Th17 cell differentiation (cytokine-producing 
capacity) of TEa cells was different. IL-17 production was 
absolutely dependent on antigen presentation, whereas some 
IFN- production could still occur in the setting of homeo-
static T proliferation within the mLNs, resulting in small 
numbers of Th1 cells (Fig. 8, a and b). Of note, this low-level 
homeostatic Th1 cell differentiation is insufficient to induce 
acute GVHD (Fig. 1 h; Koyama et al., 2012). Thus, alloantigen 
presentation is crucial for full T cell expansion and differen-
tiation during GVHD.
These results demonstrate that DAMP/PAMP signals gen-
erated during GVHD enhance alloantigen presentation and 
cytokine production by donor DCs within the mLNs, which 
promote alloreactive T cell expansion and differentiation 
therein, before donor T cell migration into the GI tract.
CCR2/ BM recipients by mixed-model analysis. Data shown are combined from two replicate experiments (n = 14 per group). (g–i) BALB/c mice were trans-
planted with TCD BM from B6.WT FLC mice or B6.CSF1R/ FLC mice with B6.WT T cells. On day 12 TEaluc+ cells were injected, and 3 d later DC subsets and TEa 
expansion were analyzed. (g) Absolute numbers of the aforementioned subsets from the mLNs are shown. *, P = 0.0152 (CD64+CD11bhi). (h and i) Representa-
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Figure 6. DAMP/PAMP signals drive alloantigen presentation by the donor CD103+CD11b DC subset within the mLNs. BALB/c mice were transplanted 
with TCD BM from B6.WT, B6.MyD88/TRIF/, or B6.RAGE/ mice with B6.WT T cells. (a–d) On day 12 TEaluc+ T cells were injected, and 3 d later BLI signals were 
measured. Representative image (a), quantification of BLI signals in mLNs (b), and ratio of BLI signals from B6.WT BM recipients to those from B6.MyD88/TRIF/ (c) 
or B6.RAGE/ (d) BM recipients by mixed-model analysis. Data shown are combined from two replicate experiments (n = 10 per group). *, P = 0.0186, B6.WT BM 
versus B6.MyD88/TRIF/ BM; *, P = 0.0187, B6.WT BM versus B6.RAGE/ BM (b). ***, P = 0.00027 (c); ****, P < 0.0001 (d), mLN versus whole body. (e–g) mLNs were 
isolated on day 12. Representative FACS plots (e and f) and absolute numbers of CD103+CD11b DC, YAe+ DC, IL-12p40+ DC, and CD64+CD11bhi macrophages in the 
mLNs (g). Data shown are combined from two replicate experiments (n = 10 per group). ****, P < 0.0001; **, P = 0.0025; *, P = 0.0131. ***, P = 0.0004, B6.WT BM versus 
B6.MyD88/TRIF/ BM (YAe+ DC); ***, P = 0.0001, B6.WT BM versus B6.RAGE/ BM (IL-12p40+DC (g). Data are represented as mean ± SEM.
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Figure 7. Donor-derived IL-12 and IL-6 drive T cell expansion and differentiation in the mLNs. BALB/c mice were transplanted with TCD BM from 
B6.WT or B6.IL-12p40/ mice (a–e) or B6.IL-6/ mice (g–k) with B6.WT T cells. TEaluc+ cells were injected on day 12, and readouts were measured 3 d later in 
mLNs. (a and g) Representative BLI pictures (left) and ratio of BLI signals from B6.WT BM recipients to those from B6.IL-12p40/ BM recipients (a) or B6.IL-6/ 
BM recipients (g) by mixed-model analysis (right). ***, P = 0.00071 (a); ****, P < 0.0001 (g) mLN versus whole body. Data shown are combined from two replicate 
experiments (n = 12 [a] or 11 [g] per group). (b, c, h, and i) Representative FACS plots (b and h) and quantification (c and i) of IFN-, IL-17A, and Foxp3 expression 
gated on TEa cells. **, P = 0.0020 for IFN- (c); *, P = 0.0396 for IL-17A (i). Data shown are combined from two replicate experiments (n = 11–12 [b and c] or 8 [h 
and i] per group ). (d, e, j, and k) Representative FACS plots (d and j) and quantification (e and k) of absolute number of DCs and their YAe expression. Data shown 
are combined from two replicate experiments (n = 7–9 [d and e] or 10–11 [j and k] per group). Data are represented as mean ± SEM. (f) BALB/c mice were trans-
planted with TCD BM and T cells from B6.CD45.1+ mice, and DC subsets were isolated by FACS sorting of mLNs combined from five mice on day 12. IL-6 quantita-
tive RT-PCR was performed. Data are shown from two separate experiments, each combining mLNs from five mice. Means are shown.
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and prevented the migration of donor T cells into the GI tract 
and systemically thereafter (Fig. 10, f and g). We confirmed 
the requirement for CCR7 in DC migration into the mLNs 
in an MHC-matched, minor histocompatibility antigen 
(miHA)-mismatched BMT model of GVHD (B6→BALB/b; 
Fig. 10 h). Furthermore, DAMP/PAMP signaling also ex-
panded the proportion of CD103+CD11b DCs in the mLNs 
in this system (Fig. 10 h). In the MHC disparate system, TEa 
cells in the mLNs from the recipients of CCR7/ BM were 
markedly reduced versus recipients of WT BM (0.08 ± 0.03 
vs.1.76 ± 0.36 × 105/mLN, P < 0.0001), with significantly 
reduced numbers of IFN-+, IL-17A+, and Foxp3+ cells (not 
depicted), similar to that seen in recipients of MHC class II/ 
BM (Fig. 8, a and b). Furthermore, TEa cells in the mLNs in 
recipients of CCR7/ BM failed to express 47 integrin, 
which was also noted in recipients of MHC class II/ BM 
(Fig. 10, i and j). Thus, donor alloantigen-presenting DCs 
migrate from the colon into the mLNs where they initiate 
T cell priming and differentiation and imprint an integrin 
expression pattern that drives migration into the intestine to 
induce lethal GVHD.
DISCUSSION
Here we delineate the organ-specific amplification of indirect 
alloantigen presentation by GVHD and the dynamics of the 
APC subsets involved therein. Surprisingly, GVHD initiated by 
recipient APCs markedly enhanced alloantigen presentation 
within the mLNs by donor CD103+CD11b DCs that drive 
lethal GVHD. Although the presence of GVHD can impair 
systemic antigen presentation by the donor CD11b+ DC sub-
set outside of the GI tract (Markey et al., 2012), the impact of 
GVHD on antigen presentation has not been investigated in an 
organ-specific manner previously. Here we show that GVHD 
increases and maintains donor DC reconstitution specifically in 
the colon and the mLNs. Furthermore, GVHD profoundly en-
hances the ability of colonic CD103+CD11b DCs to present 
alloantigen and secrete IL-12, before their CCR7-dependent 
migration into the mLNs. Within the mLNs these DCs expand, 
differentiate, and imprint an integrin signature on alloreactive 
T cells, which result in the accumulation of pathogenic Th1 
cells in the GI tract, culminating in fulminant GVHD (depicted 
in Fig. S1). It is likely that donor T cells emigrating to the colon 
will encounter tissue DCs presenting alloantigen therein and 
undergo further activation, differentiation, and cytokine release 
in situ. Because donor T cells in this system cannot make cog-
nate interaction with target tissue by virtue of their TCR-
MHC restriction, the exacerbation of GVHD will instead 
be mediated by inflammatory cytokines, consistent with this 
as a known dominant pathway in CD4-dependent GVHD 
(Teshima et al., 2002).
DAMP/PAMP signaling via TLRs has been recognized 
to play a crucial role in GVHD (Blazar et al., 2012; Heidegger 
et al., 2014) caused by donor cells (Cooke et al., 1998), an 
effect thought to be via the induction of proinflammatory 
cytokines. Here we demonstrate that a major effect of these 
DAMPs/PAMPs through MyD88/TRIF signaling is to en-
hance alloantigen presentation. We also confirm a similarly 
important role for the RAGE pathway. Our data also demon-
strate that the DAMP/PAMP signals influence not only the 
function but also the expansion of donor CD103+CD11b 
DCs. In contrast, recipient hematopoietic APCs are in a state 
Figure 8. T cell expansion and differentiation are dependent on 
indirect antigen presentation. BALB/c mice were transplanted with 
TCD BM from B6.WT or B6.H2-Ab1/ mice and B6.WT T cells. On day 12 
TEa T cells were injected, and 3 d later TEa cells from spleen (Sp), mLNs, 
and pLNs were quantified. (a) Quantification of absolute number of TEa 
cells (Vb6+Va2+CD8CD90.2+) and frequency and absolute numbers of 
IFN-–, IL-17A–, and Foxp3-expressing TEa cells in mLNs. (b) Represen-
tative FACS plots. Data shown are combined from two replicate experi-
ments (n = 11–12 per group for TEa counts, IFN-, and IL-17A; n = 6 per 
group for Foxp3). ****, P < 0.0001; **, P = 0.0032; *, P = 0.041. Data are 
represented as mean ± SEM.
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Figure 9. Donor DCs presenting alloantigen expand in the colon during GVHD. (a–d) BALB/c mice were transplanted with TCD BM from B6.CD11c.
GCDL mice (where luciferase is driven off the CD11c promoter) with or without B6.WT T cells, and BLI signals were quantified thereafter (to determine 
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of elimination by conditioning therapy and appear to have a 
very limited capacity to expand after BMT (Zhang et al., 2002), 
likely explaining the reported lack of effect of the DAMP/
PAMP pathways in this compartment (Li et al., 2011). More-
over, such enhanced donor DC expansion and function in the 
GI tract may exacerbate not only acute but perhaps also chronic 
GVHD because it has been demonstrated that donor APCs 
play a dominant role in this setting (Anderson et al., 2005).
Donor CD103+CD11b DCs in the colon and the mLNs 
are the key players in indirect alloantigen presentation after 
BMT. Nonlymphoid tissue CD103+CD11b DCs corre-
spond to the CD8+CD11b LN DCs and develop from pre-DC 
precursors but not monocytes at steady-state (Bogunovic 
et al., 2009; Varol et al., 2009). They are known to efficiently 
cross-present antigen and activate CD8+ T cells (Shortman 
and Heath, 2010; Merad et al., 2013), but their ability to acti-
vate CD4+ T cells is less clear. In addition, although inflam-
matory stimuli can increase DCs in the LNs, the origin of 
these inflammatory DCs remains unclear (Merad et al., 2013). 
Although monocytes had been considered progenitors (Auffray 
et al., 2009; Domínguez and Ardavín, 2010), hematopoietic 
stem cells have recently been described to give rise to CD11c+ 
cells rapidly after LPS stimulation (Nagai et al., 2006; Massberg 
et al., 2007). We demonstrate that, like CD8+ DCs in naive 
mice, the majority of donor CD103+CD11b DCs in the 
mLNs also express CD8 (Fig. S2). CCR2 controls monocyte 
recruitment from blood to inflamed tissue (Tsou et al., 2007), 
and we found that alloreactive T cell expansion was identical 
in recipients of CCR2-deficient and WT grafts (Fig. 5, b–f). 
Thus, the donor DCs essential for indirect alloantigen presen-
tation in the mLNs would appear to be derived from the stem 
cell compartment rather than monocytes.
Consistent with previous studies (Maldonado-López et al., 
1999; Fujimoto et al., 2011), CD103+CD11b DCs produce 
high amounts of IL-12p40 after BMT, and the absence of this 
cytokine reduced T cell expansion and Th1 cell differentia-
tion. Notably, antigen presentation in isolation was not crucial 
for the generation of IFN-–producing donor T cells. Thus, 
MHC class II or CCR7-deficient donor DCs had minimal 
capacity to expand antigen-specific donor T cells and invoke 
Th17 cell differentiation, but some Th1 cell differentiation 
still occurred in this lymphopenic environment. However, it 
must be noted that the overall number of Th1 cells expanded 
in the absence of antigen presentation was very low. These 
findings are consistent with our previous observation that the 
complete absence of I-Ab in BMT recipients did not completely 
prevent IFN- production by TEa cells (Koyama et al., 2012). 
However, in this setting the numbers generated are very low, 
they are not imprinted with 47, and they are unable to in-
duce acute GVHD (Fig. 1 h; Koyama et al., 2012). Th17 cell 
differentiation required IL-6, and among DCs, this appeared to 
be predominantly derived from the CD103+CD11b+ subset. 
However, there is likely to be significant redundancy in the 
source of IL-6 after BMT because Th17 cell differentiation still 
occurred in recipients of IRF4/ BM, which lack this popula-
tion. Indeed, IL-6 is the principal dysregulated inflammatory 
cytokine after allogeneic BMT, and systemic levels are very 
high for 2 wk after BMT (Kennedy et al., 2014). Interestingly, 
we demonstrate that both IL-12 and IL-6 can expand alloreac-
tive T cells within the gut independent of any effect on antigen 
presentation, providing an important rationale for their inhibi-
tion in the clinical setting. Indeed, we have recently demon-
strated in a phase I/II study that the inhibition of IL-6 early 
after BMT is associated with very low levels of acute GVHD 
(Kennedy et al., 2014).
Surprisingly, antigen presentation by donor DCs exclu-
sively controlled the expression of gut-homing integrins. 
Given that donor T cells cannot induce GVHD without allo-
antigen presentation (Koyama et al., 2012), these data demon-
strate that Th1 T cells are insufficient to induce and/or maintain 
GVHD without the imprinting of gut tropism. As has been 
demonstrated for pathogens (Stagg et al., 2002; Johansson-
Lindbom et al., 2005), we demonstrate that during GVHD this 
process is critically dependent on MHC class II presentation by 
donor DCs migrating from the colon. Together, these findings 
identify the hitherto unappreciated importance of indirect 
alloantigen presentation, amplified by GVHD, to the genera-
tion of lethal disease. We thus identify several molecular targets 
to prevent the development of severe GVHD in the clinic. 
These highlight first and foremost the importance in prevent-
ing GVHD and the feed-forward cascade thereafter that culmi-
nates in lethality. The cellular and molecular switches involved 
include the donor CD103+CD11b DC subset, IL-12, IL-6, 
DAMPs/PAMPs, and the RAGE pathway. Inhibition of the 
IL-6 receptor with tocilizumab, a humanized monoclonal 
antibody, has shown promise in reducing the incidence of acute 
GVHD, including intestinal GVHD, in a phase I/II clinical 
trial (Kennedy et al., 2014). Likewise, IL-12 blocking anti-
bodies (ustekinumab) and RAGE inhibitors (FPS-ZM1) are 
now available (Henden and Hill, 2015). Therapeutic approaches 
inhibiting this amplification cascade within acute GVHD can 
thus now be tested in the clinic.
donor DC expansion). Experimental schema (a), representative BLI on days 3, 5, 12, and 21 (b), quantified BLI signals in colon, small intestine, and mLNs 
(c), and ratio of BLI signals from mice receiving BM and B6.WT T cells to those from mice receiving TCD BM alone on day 12 by mixed-model analysis (d). 
Time course shown in c is combined from three experiments (n = 3–9 per time point). Data on days 5, 8, 12, and 21 are combined from two replicate ex-
periments. *, P = 0.0499, day 12 versus day 21 of BM + T in small intestine; ***, P = 0.002, day 12 versus day 21 of TCD BM in mLN; BM + T versus TCD BM 
****, P < 0.0001 (day 21); ***, P = 0.0009 (day 12); **, P = 0.0093 (day 28) in colon; ****, P < 0.0001 (days 12 and 21) in small intestine; ***, P = 0.0006 (day 
21); *, P = 0.0257 (day 28) in mLNs. (e) BALB/c mice were transplanted with TCD BM with or without T cells from B6.IL-12p40-YFP (CD45.2+) mice. Repre-
sentative FACS plots of the CD3NKp46CD45.2+ fraction from the isolated colon, small intestine, and mLNs on day 12 are shown and are representative 
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Figure 10. Colon-derived donor DCs migrate to the mLNs via CCR7 and imprint the 47 gut-homing integrin on donor T cells. (a–g, i, and 
j) BALB/c mice were transplanted with TCD BM from B6.WT, B6.CCR7/, or B6.H2-Ab1/ mice with B6.WT T cells. (a and b) Colon and mLNs were isolated 
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Total flux of mouse or organ is presented as photons per second (ph/s). Mice 
were injected with 500 µg d-Luciferin (subcutaneously; PerkinElmer) and 
imaged 5 min later.
Cell isolation from small intestine and colon. Small intestine and colon 
were removed, cut longitudinally into 3–5-mm pieces, and washed three 
times with PBS. The pieces were incubated under stirring in Ca/Mg-free 
PBS containing 5 mM EDTA (Chem-Supply) for 30 min at 37°C. Cells 
were isolated by passing through a 100-µm cell strainer. Suspended cells 
were kept as the intraepithelial leukocyte (IEL) fraction. The remaining 
pieces of tissue were incubated for 30 min at 37°C in RPMI including 5 µg/ml 
DNase + 5 µg/ml Collagenase 4 (Sigma-Aldrich) and then passed through 
a 100-µm cell strainer to obtain the lamina propria leukocyte (LPL) fraction. 
IEL and LPL fractions were combined for FACS analysis. In some experi-
ments using colon, longitudinally cut pieces were processed with Gentle 
MACS (Miltenyi Biotec) according to the manufacturer’s protocol.
FACS analysis. FITC-conjugated antibodies to CD45.1, CD45.2, H-2Dd, 
MHC class II (I-A/I-E), and IgG2a isotype control; PE-conjugated antibod-
ies to CD11c, CD103, I-Ab, IFN-, CD40, CD80, CD86, CD115, Arme-
nian Hamster IgG, and rat IgG2a isotype controls; PerCPCy5.5-conjugated 
antibody to CD11b; Cy7 PE (PeCy7)–conjugated antibodies to CD45.1, 
CD3, NKp46, CD64, and rat IgG2b isotype controls; allophycocyanin- 
conjugated antibodies to CD45.2, CD3, NK1.1, CD11c, CD103, CCR7, rat 
IgG2a, and rat IgG2b isotype control; Alexa Fluor 647–conjugated H-2Dd, 
I-Ad, Foxp3, mouse IgG1, and rat IgG2b isotype controls; Alexa Fluor 700–
conjugated antibodies to CD45.1, F4/80, IL-17A, rat IgG2a, and IgG2b 
isotype controls; allophycocyanin-Cy7–conjugated antibody to CD11c; and 
Pacific Blue–conjugated I-A/I-E, Brilliant Violet 605–conjugated streptavidin, 
and antibody to CD90.2 were purchased from BioLegend. FITC-conjugated 
or biotin-conjugated antibodies to V6, PE, or allophycocyanin-Cy7– 
conjugated antibodies to V2, Alexa Fluor 647–conjugated antibody to 
CD64 (a and b), and Alexa Fluor 700–conjugated antibody to CD45.2 were 
purchased from BD. Biotinylated antibodies to YAe and mouse IgG1 were 
purchased from eBioscience. The YAe antibody reacts with Ea peptide (pep-
tide 52–68) bound to I-Ab (the same complex recognized by TEa cells). 
Allophycocyanin-conjugated antibody to CCR2 was purchased from R&D 
Systems. FITC-conjugated rat IgG2b isotype control (MAC5) was made in 
our laboratory. LIVE/DEAD Fixable Aqua Dead Cell Stain kit from Thermo 
Fisher Scientific was used to exclude dead cells according to the manufactur-
er’s protocol. Foxp3 expression level with IFN- and IL-17A was deter-
mined using the Foxp3 staining buffer set (eBioscience) according to the 
manufacturer’s protocol.
Mixed lymphocyte cultures. Mixed lymphocyte cultures were set up in 
triplicate in round-bottom 96-well plates (Falcon; BD) using sort-purified 
TEa T cells stimulated with CD11c+ DCs from BALB/c recipients trans-
planted with BM and T cell of B6.WT mice 12 d after BMT, which were 
positively selected using CD11c beads and the magnetically activated cell 
sorter (MACS) system (Miltenyi Biotec) as previously described (Markey 
et al., 2010). TEa proliferation was determined by [3H]thymidine uptake.
MATERIALS AND METHODS
Mice. BALB/b (H-2b, CD45.2+), C57BL/6 (B6.WT, H-2b, CD45.2+), 
C57BL/6 background Ptprca (B6.CD45.1+, H-2b, CD45.1+), and BALB/c 
(H-2d, CD45.2+) were purchased from the Animal Resources Centre. Trans-
genic and knockout mice on a B6 background originated as follows: B6.IL-
12p40YFP, C.R. Engwerda; BALB/c background Ptprca (BALB/c.CD45.1+, 
H-2d, CD45.1+), B6.IL-12p40/, and B6.CCR2/, M.J. Smyth; B6.CD11c.
ova and B6.OT-II, R. Steptoe, University of Queensland (UQ), St. Lucia, 
Queensland, Australia; HY-TCR, A. Strasser, Walter and Eliza Hall Institution 
(WEHI), Melbourne, Victoria, Australia (Bouillet et al., 2002); B6.H2-Ab1/, 
referred to as MHC class II/, Australian National University, Canberra; B6.
CD11c.GCDL, G. Hammerling, Deutsches Krebsforschungszentrum, Moleku-
lare Immunologie, Heidelberg, Germany (Tittel et al., 2012); -actin–luciferase, 
R. Negrin, Stanford University, Stanford, CA (Nishimura et al., 2008); TEa, 
J. Bromberg, Albert Einstein College of Medicine, Bronx, NY (Ochando et al., 
2006); B6.IRF4/, G.T. Belz (Mittrücker et al., 1997; Cretney et al., 2011); 
B6.MyD88/TRIF/, S. Akira, Osaka University, Osaka, Japan (Yamamoto 
et al., 2003); B6.RAGE/, S. Phipps, UQ (Chen et al., 2008); CCR7/, 
S.R. McColl (Bunting et al., 2013); and B6.CSF1R–/+, R. Stanley, Albert Einstein 
College of Medicine (Alexander et al., 2014). TEa transgenics were similarly 
bred onto -actin–luciferase (TEaluc+) and CD45.1+ backgrounds. Mice were 
bred at the QIMR Berghofer Medical Research Institute animal facilities. Mice 
including donors and recipients were female except the experiments as described 
using HY-TCR transgenics. Mice were housed in sterilized microisolator cages 
and received acidified autoclaved water, pH 2.5, after transplantation. All animal 
maintenance and procedures were undertaken using protocols approved by the 
institutional (QIMR) animal ethics committee.
Stem cell transplantation and reporter cell injection. BALB/c and 
BALB/b mice were transplanted as described previously (Morris et al., 2005) 
after 900 cGy total body irradiation (TBI; 137Cs source at 84 cGy/min) on day 
1. On day 0, mice were transplanted with 10 × 106 BM cells from B6.WT 
or the indicated B6 background transgenic mice with or without 2 × 105 
FACS-purified B6.WT T cells (>98%; CD90.2+). BM cells were depleted of 
T cells (TCD) by antibody and complement as previously described (MacDonald 
et al., 2007). For reporter assays, recipients were injected intravenously on day 
12 with 2 × 106 TEa T cells, 106 HY-TCR CD8 Tg T cells, or 2 × 106 OT-II 
T cells to report alloantigen presentation. TEa (>98%; V6+V2+), HY-TCR 
CD8 Tg (>98%; CD4CD90.2+), and OT-II (>98%; V5+V2+) cells were 
purified by sorting (MoFlo [Beckman Coulter] or FACSAria [BD]) as de-
scribed previously (Markey et al., 2010). CFSE labeling has been described 
previously (Reddy et al., 2001; Banovic et al., 2005). For donor DC depletion, 
mice received 100 ng DT intraperitoneally every 2 d from day 8 to the day 
before analysis. The degree of systemic GVHD was assessed by scoring as pre-
viously described (maximum index = 10; Hill et al., 1997). For survival exper-
iments, transplanted mice were monitored daily, and those with GVHD 
clinical scores ≥6 were sacrificed and the date of death registered as the next 
day, in accordance with institutional guidelines.
BLI. TEaluc+ T cell expansion was analyzed by luciferase signal intensity 
(Xenogen IVIS 100; Caliper Life Sciences). Light emission is presented as 
photons per second per square centimeter per steer radiant (ph/s/cm2/sr). 
on day 12. Representative FACS plots (a) and the absolute numbers of CD64 DC, YAe+CD64 DC, and CD64+CD11bhi subsets (b). Data shown are  
combined from three replicate experiments (n = 7–8 per group). ****, P < 0.0001; ***, P = 0.0003; *, P = 0.0413. (c–g, i, and j) On day 12 TEaluc+ T cells were 
injected, and 3 (c–e, i, and j) or 5 d (f and g) later BLI signals and cells from spleen, mLNs, and pLNs were analyzed. Representative BLI (c and f) and quan-
tification of BLI signals (d and g). ****, P < 0.0001; **, P = 0.0012. (e) Ratio of BLI signals from B6.WT BM recipients to those from B6.CCR7/ BM recipi-
ents by mixed-model analysis. ****, P < 0.0001; **, P = 0.00301 versus whole body. Data shown are combined from two replicate experiments (n = 9–10 
per group). (h) BALB/b (H-2b) mice were transplanted with TCD BM from B6.WT, B6.CCR7/, or B6.MyD88/TRIF/ mice with B6.WT T cells, and mLNs 
were isolated on day 12. The absolute numbers of CD64 DCs and the frequency of the CD103+CD11b DC subset are shown. Data shown (n = 4 per 
group) are representative of two replicate experiments. *, P = 0.0286 (CD64 DC); *, P = 0.0367 (% CD103+CD11b). (i and j) Representative FACS plots (i) 
and quantification (j) for 47 integrin expression, gated on TEa cells. Data shown are combined from two replicate experiments (n = 6–9 per group). ****, 
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Cytokine analysis. For direct cytokine detection, cells were stimulated 
ex vivo by 50 ng/ml PMA and 500 ng/ml ionomycin for 4 h at 37°C, and 
1 µg/ml brefeldin A was added for the last 3 h. After surface staining, cells 
were fixed and permeabilized using the eBioscience Foxp3 intracellular 
staining kit, followed by staining of Foxp3, IFN-, and IL-17A. For IL-
12p40 staining, cells were incubated with GolgiPlug (1 in 1,000 dilution; 
BD) for 4 h, followed by intracellular cytokine staining using the Cytofix/
Cytoperm kit as per the manufacturer’s protocol (BD). For quantitative 
PCR analyses, total RNA was extracted with the RNeasy Micro kit (QIA-
GEN) from sort-purified (>95% purity) cells and gene expression deter-
mined using TaqMan gene expression assays (Applied Biosystems). All 
measurements were run in parallel with the housekeeping gene hprt as an 
endogenous control. Data were normalized to both endogenous control and 
splenic CD103+ DC population.
Statistical analysis. The natural log of bioluminescence values was taken 
before analysis. All other measurements (percentages and cell counts) re-
mained untransformed. When experiments were replicated on separate days, 
the results were combined and analyzed via a two-way ANOVA where the 
two factors were day and experimental group. If there were no replications 
on separate days, a one-way ANOVA was performed. However, an ANOVA 
was only performed if the equality of variance tests indicated the group vari-
ances were not significantly different (P > 0.01). Otherwise an appropriate 
nonparametric test was performed. The mean ± SEM for the raw data 
(calculated on the linear scale) is presented.
To assess the differences in the decrease (or increase) in log biolumines-
cence for the experiment group relative to the appropriate WT, a mixed-
model with mouse as a random effect was fitted and the interaction of organ 
by group was tested. If significant, a post-hoc comparison was performed by 
defining a contrast matrix and calculating a standard error estimate as per 
Cochran and Cox (1957), and the degrees of freedom were similarly calcu-
lated. The mean ± SEM for the ratio of the WT group to the appropriate ex-
perimental group for each organ was calculated on the log scale using the 
weighted standard error estimate as detailed above and then back transformed 
for ease of interpretation. For survival data, Kaplan-Meier curves were com-
pared using the log-rank test. Where applicable, all p-values were corrected 
for multiple comparisons using the Bonferroni correction.
Online supplemental material. Fig. S1 depicts the proposed feed-forward 
cascade of acute GVHD mediated by colon-derived donor DCs. Fig. S2 
shows the gating strategy of DCs in naive and post-BMT recipients. Online 
supplemental material is available at http://www.jem.org/cgi/content/full/ 
jem.20150329/DC1.
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